APPRECIATE™ (APREmilast ClinIcAl Treatment Experience in psoriasis): A Multi-center, Retrospective Observational Study of Real-World Experience of Psoriasis Patients Treated with Apremilast in Clinical Dermatology Practice.(20200066 / CC-10004-PSOR-013)

Study type

• Study topic:
  Human medicinal product

  Disease /health condition
• Study type:
  Non-interventional study
• Scope of the study:
  Other
• If ‘other’, further details on the scope of the study:
  Observational study
• Data collection methods:
  Primary data collection

Non-interventional study

• Non-interventional study design:
  Cross-sectional

Study drug and medical condition

• Name of medicine:
  OTEZLA
• Medical condition to be studied:
  Psoriasis

Population studied

• Short description of the study population:
  Patients treated for psoriasis with apremilast and their physicians completing questionnaires at 6 (±1) months after initiation of apremilast.
• Age groups:
  Adults (18 to < 46 years)

  Adults (46 to < 65 years)

  Adults (65 to < 75 years)

  Adults (75 to < 85 years)

  Adults (85 years and over)
• Special population of interest:
  Other
• Special population of interest, other:
  Psoriasis patients
• Estimated number of subjects:
  610

Study design details

• Main study objective:
  The main objective of this study is to describe the treatment patterns and outcomes among apremilast users in routine clinical dermatology practice, from the physician and patient perspective.
• Data analysis plan:
  Analyses will primarily be performed using descriptive and correlational statistical methods.

Documents

Study results

20200066 ORSR Abstract 20May2022_Redacted